Nazar-Stewart V, Motulsky A G, Eaton D L, White E, Hornung S K, Leng Z T, Stapleton P, Weiss N S
Department of Epidemiology, University of Washington, Seattle 98195.
Cancer Res. 1993 May 15;53(10 Suppl):2313-8.
Glutathione S-transferase (GST) enzymes detoxify carcinogens in tobacco smoke. Interindividual variation in GST function may be related to differences in risk for smoking-related cancer. Leukocytes from 50% of Caucasians lack GST activity toward trans-stilbene oxide (TSO), due to a deletion of the gene for the GST-mu enzyme. Presence of GST-TSO activity in leukocytes has been associated with low risk for lung cancer among cigarette smokers. We sought to determine whether GST activity in lung tissue is determined by the same gene polymorphism and whether it is associated with risk for lung cancer. Subjects were cigarette smokers, identified at the time of lung resection or autopsy in Seattle hospitals. Uninvolved lung tissue was obtained from 35 patients with lung carcinoma and 43 control patients and assayed for GST-mu activity with TSO, for the presence of the GST-mu gene product with an immunological assay, and for the GST-mu gene with Southern blotting. Mailed questionnaires were used to collect information on subjects' smoking histories and exposures which might alter enzyme activity. Interindividual results from the three assays correlated well. Smokers with high GST-TSO enzyme activity present in their lung tissue had a lower risk for lung carcinoma than did smokers with no or low activity (relative risk = 0.30; 95% confidence interval, 0.11-0.79), as did smokers with GST-mu antigen identified in lung tissue versus those with no antigen (relative risk = 0.30; 95% confidence interval, 0.11-0.79). Smokers with both maternal and paternal copies of GST-mu DNA (n = 7) had a lower cancer risk than smokers lacking GST-mu DNA (n = 30; relative risk = 0.35; 95% confidence interval, 0.06-2.10). High GST-mu activity appeared to be associated with a greater decrease in lung cancer risk among 38 heavy cigarette smokers (relative risk = 0.15; 95% confidence interval, 0.03-0.64) than among 38 light smokers (relative risk = 0.61; 95% confidence interval, 0.14-2.60). Presence or absence and number of copies of the GST-mu gene appear to determine activity of the GST-mu enzyme in lung. Smokers with the GST-mu enzyme have approximately one-third of the risk for lung carcinoma of smokers without the enzyme.
谷胱甘肽S-转移酶(GST)可使烟草烟雾中的致癌物解毒。GST功能的个体差异可能与吸烟相关癌症风险的差异有关。50%的高加索人的白细胞缺乏对反式氧化茋(TSO)的GST活性,这是由于GST-μ酶基因的缺失。白细胞中存在GST-TSO活性与吸烟者患肺癌的低风险相关。我们试图确定肺组织中的GST活性是否由相同的基因多态性决定,以及它是否与肺癌风险相关。研究对象为吸烟者,在西雅图医院进行肺切除或尸检时确定。从35例肺癌患者和43例对照患者中获取未受累的肺组织,用TSO检测GST-μ活性,用免疫分析法检测GST-μ基因产物的存在情况,并用Southern印迹法检测GST-μ基因。通过邮寄问卷收集有关研究对象吸烟史和可能改变酶活性的暴露情况的信息。三种检测方法的个体结果相关性良好。肺组织中存在高GST-TSO酶活性的吸烟者患肺癌的风险低于无活性或低活性的吸烟者(相对风险=0.30;95%置信区间,0.11-0.79),肺组织中检测到GST-μ抗原的吸烟者与未检测到抗原的吸烟者相比也是如此(相对风险=0.30;95%置信区间,0.11-0.79)。同时拥有父母双方GST-μ DNA拷贝的吸烟者(n=7)患癌症的风险低于缺乏GST-μ DNA的吸烟者(n=30;相对风险=0.35;95%置信区间,0.06-2.10)。在38名重度吸烟者中,高GST-μ活性似乎与肺癌风险的更大降低相关(相对风险=0.15;95%置信区间,0.03-0.64),而在38名轻度吸烟者中则不然(相对风险=0.61;95%置信区间,0.14-2.60)。GST-μ基因的存在与否及拷贝数似乎决定了肺中GST-μ酶的活性。具有GST-μ酶的吸烟者患肺癌的风险约为没有该酶的吸烟者的三分之一。